Description
Bortezomib (CAS 179324-69-7) is a potent inhibitor of 20S proteasome with Ki of 0.6 nM. A selective and robust 26S proteasome inhibitor, that is a boronic acid dipeptide derivative. Human pancreatic cancer cell studies demonstrate Bortezomib to inhibit the PKR-like endoplasmic reticulum (ER) kinase and enhance ER stress, leading to apoptosis. Studies suggest that Bortezomib affects the gene expression of WT1, and blocks the function of human plasmacytoid DCs through the inhibition of intracellular trafficking of Toll-like receptors and modification of the ER homeostasis. Bortezomib has been reported to inhibit necrosis and cell proliferation, and downregulate metastatic gene expression.